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Abstract 
 
 The myeloproliferative neoplasms including polycythemia vera, essential 
thrombocythemia and myelofibrosis, are distinguished by their debilitating 
symptom profiles, life-threatening complications and profound impact on quality 
of life. The role gender plays in myeloproliferative neoplasm symptomatology 
remains under-investigated. In this study, we evaluated how gender relates to 
patient characteristics, disease complications and overall symptom expression.  
A total of 2006 patients (polycythemia vera=711, essential 
thrombocythemia=830, myelofibrosis=460, unknown=5) were prospectively 
evaluated with patients completing the MPN-SAF and Brief Fatigue Inventory 
Patient Reported Outcome tools.  Information on individual patient 
characteristics, disease complications and laboratory data was collected. 
Consistent with known literature, most female patients were more likely to have 
essential thrombocythemia (48.6% vs. 33.0%; p<0.001) and most male patients 
were more likely to have polycythemia vera (41.8% vs. 30.3%; p<0.001). Males 
demonstrated higher rates of thrombocytopenia (13.9% vs. 8.2%; p<0.001) and 
had higher red-blood cell transfusion requirements (7.3% vs. 4.9%; p=0.02) with 
lower mean disease durations (6.4 vs. 7.2 years, p=0.03).  Despite no statistical 
differences in risk scores, receipt of most therapies or prior complications 
(hemorrhage, thrombosis), females had more severe and more frequent 
symptoms for most individual symptoms, along with overall total symptom score 
(22.8 vs. 20.3; p<0.001). Females demonstrated particularly burdensome scores 
for abdominal-related symptoms (abdominal pain/discomfort) and microvascular 
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symptoms (headache, fatigue, insomnia, concentration difficulties, dizziness; all 
p<0.01). Despite vocalizing more severe symptom burdens, females documented 
similar quality of life scores to males. The results of this study suggest that 
gender contributes to myeloproliferative neoplasm heterogeneity by influencing 
phenotypic profiles and symptom expression. 
 5 
Introduction 
 
 The Myeloproliferative neoplasms (MPNs) have an acquired reputation for 
molecular complexity, clinical heterogeneity and profound impact on length and 
quality of life. Polycythemia vera (PV), essential thrombocythemia (ET) and 
myelofibrosis (MF) are debilitating MPNs associated with arterial and venous 
thrombosis, cytopenias, marked splenomegaly, persistent constitutional 
symptoms and predilection for transformation to acute myelogenous leukemia 
(AML) or MF (in ET and PV).  
 
 Understanding how gender impacts MPN development, disease 
manifestation and progression has been a topic of emerging interest.  As 
exemplified by increased prevalence of females in ET and males in PV, it has 
long been recognized that males and females may be impacted discordantly. 
However, advancing literature supports the potential for gender to influence 
genotypic expression and potentially clonal expansion.  A recent investigation 
evaluating gene expression in circulating CD34+ cells from 19 JAK2V617F 
positive PV patients identified reduced gene expression in females (235 genes) 
as compared to males (571), while activating more than three times as many 
molecular pathways.1 Females have also been shown to have dramatically lower 
JAK2V617F allele burdens.2,3 More recent data has uncovered the existence of 
female-dominant MPN clusters (both PV and ET) typified by a high prevalence of 
laboratory abnormalities and sexuality-related complaints.4   
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 Despite these new insights, little is known about how gender relates to 
symptomatic profiles. The timely development of MPN-specific Patient Reported 
Outcome (PRO) tools has allowed us to objectively quantify the MPN symptom 
burden and evaluate its impact on quality of life.  The Myelofibrosis Symptom 
Assessment Form (MF-SAF), Myeloproliferative Neoplasm Symptom 
Assessment Form (MPN-SAF) and MPN-10 have been applied in both clinical 
and trial settings, yielding significant insight into how observed clinical and 
symptomatic heterogeneity may, in fact, follow predictable patterns and/or harbor 
otherwise unrecognized associations.  In this study, we examine associations 
between gender and patient symptomatology, along with disease features, 
laboratory abnormalities and overall quality of life.  
 
 
Methods 
 
Survey Development and Collection:  
  This study was approved by the Mayo Clinic Institutional Review Board 
(IRB). Data was collected among an international cohort of patients with MPNs 
including ET, PV and MF.  All patients were recruited via mechanisms described 
previously during the validation of the MPN-SAF.5  A description of MPN SAF 
PRO development and validation may be found in Appendix 1.  The process for 
language translation may also be found in Appendix 1 and is based on standard 
PRO translational methods.6 In addition to the MPN-SAF, subjects also 
completed the Brief Fatigue Inventory (BFI)7. Data was collected in the English, 
Dutch, Italian, French, German, Chinese, Swedish and Spanish languages. 
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Gender was recorded based on patient self-reporting under the question of ‘sex’ 
with respondent options of ‘male’ or ‘female’.  Evaluation of cultural/regional 
variations in symptom expression involved comparison of Chinese patients with 
‘Western’ patients which were composed of predominantly Caucasian individuals 
from western Europe and the United States of America. 
 
Symptom Evaluation: 
  Symptoms listed on the MPN-SAF included the patient’s perceptions of 
common MPN-related symptoms and overall quality of life (QOL) on a 0 (absent) 
to 10 (worst imaginable) scale. Assessed symptoms included items related to 
sad mood, quality of life, inactivity, concentration problems, abdominal 
pain/discomfort, dizziness, insomnia, night sweats, worst fatigue, early satiety, 
bone pain, numbness, cough, itching, headache, fever and weight loss. Total 
symptom score (TSS) was computed based on 10 symptom items. For 
individuals completing at least 6 of the 10 MPN-SAF TSS items, the survey was 
scored by multiplying the average score across items by 10 to achieve a 0 to 100 
scaled score. 
 
Prognostic Scoring: 
 Prognostic scoring for ET was calculated using the International 
Prognostic Scoring for Essential Thrombocythemia (IPSET).8 This scoring 
system includes the variables of leukocyte count >/= 11 x 10(9)/L (1 point), 
age>/=60 (2 points), and history of thrombosis (1 point) to risk stratify patients to 
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low risk (0 points), intermediate risk (1-2 points) or high risk (3-4 points). 
Prognostic scoring for PV survival was calculated using the Leukemia 2013 
prognostic scoring model.9 This scoring system includes the variables of age 
>/=67 (5 points), age 57-66 (2 points), prior thrombosis (1 point) and WBC >/=15 
x 10(9)/L (1 point) to risk stratify patients into low-risk (0 points), intermediate risk 
(1-2 points) and high risk (>/=3 points).  Prognostic scoring for MF survival was 
calculated using the Dynamic International Prognostic Scoring System 
(DIPSS).10 This scoring model includes the variables of hemoglobin <10 g/dL (2 
points), age >/=65 (1 point), white blood cell count >/= 25 x 10(9)/L (1 point), the 
presence of constitutional symptoms (1 point) and >/=1 percent blasts (1 point) to 
risk stratify patients into low risk (0 points), intermediate-1 risk (1-2 points), 
intermediate-2 risk (3-4 points) and high risk (>4 points). 
 
Statistical Analysis: 
 All patient symptom comparisons were adjusted for MPN type and age.  
Continuous variables were compared using analysis of variance and 
dichotomous data were compared using chi-square test. Statistical significance 
was set at p<0.05. SAS version 9.3 (Cary, NC) was used for analysis. 
 
Results 
Patient Demographics 
 A total of 2006 (male; n=917 / female; n=1089) MPN patients completed 
the MPN-SAF and BFI (Table 1).  MPN subtypes included polycythemia vera 
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(n=711), essential thrombocythemia (n=830) and myelofibrosis [n=460; PMF 
(68.3%); post-ET MF (18%); post-PV MF (13.7%)].  Patients were of expected 
age (mean 59.9 years, range 15-94) for the disorders and composed primarily of 
Chinese (27.1%) and French (23%) language groups. When separated by risk 
categories, most MF patients met DIPSS intermediate-1 risk (54.5%) followed by 
intermediate-2 risk (24.3%), low risk (18.3%) and high risk (3%).  Most ET 
patients met intermediate risk (46.7%), followed by low risk (36.0%) and high risk 
(17.3%). For PV, most patients were in the high risk category (49.5%) followed 
by intermediate risk (29.7%) and low risk (20.7%). Mean hemoglobin (13.4, SD 
3.17), white blood cell count (WBC, 8.9, SD 7.15), and platelet count (429.5, SD 
269.72) were evaluated, along with laboratory abnormalities including anemia 
(8.5%), thrombocytopenia (10.7%) and leukopenia (10.0%).  Prior thrombosis 
(21.2%) and prior hemorrhage (5.4%) were relatively uncommon and most 
patients (94.0%) had no red blood cell transfusion requirements. 
 
Clinical Factors 
 When comparing clinical factors between genders, female patients were 
found to be slightly younger (59.3 vs. 60.7 years, p=0.02) with more patients 
under age 60 at the time of data collection (48.9% vs. 43.4%, p=0.01; Table 1).  
The prevalence of MPN subtypes also differed by gender (p=0.01) with most 
females having a diagnosis of ET (48.6%), followed by PV (30.3%) and MF 
(21.2%) and most male patients having a history of PV (41.8%) followed by ET 
(33.0%) and MF (25.2%).  Gender distribution also differed by MPN subtype with 
 10
PMF more prevalent in males (74.8% vs. 61.7%; p=0.01), and post-ET MF more 
common in females (21.7% vs. 14.3%; p=0.01).  Mean hemoglobin (13.8 vs. 13.0 
g/dL, p<0.001) and white blood cell counts (9.5 vs. 8.5 x 10(9)/L, p=0.004) were 
higher in males whereas females demonstrated higher platelet counts (454.1 vs. 
399.5 x 10(9)/L, p<0.001).  Thrombocytopenia was most common in males 
(13.9% vs. 8.2%, p<0.001) and no differences were noted in prevalence of 
anemia or leukopenia (p>0.05).  Males were also more likely to have a history of 
red blood cell transfusion requirements (7.3% vs. 4.9%, p=0.02).  Risk scores, 
language prevalence, history of prior thrombosis or hemorrhage did not differ by 
gender (all p>0.05).  Prior thrombosis was further stratified by gender and MPN 
type.  No differences were noted in ET (male 23.5% vs. female 19.3%, p=0.156), 
PV (male 26.7% vs. 29.8%, p=0.339) or MF (male 12.8% vs. female 9.7%, 
p=0.298). Few differences were noted between genders when compared by prior 
therapies with the exception of higher rates of phlebotomy/venesection and 
givinostat/vorinostat use in males (both p<0.05; Figure 1). 
 
MPN Symptoms by Gender 
 After adjusting for MPN subtype and age, overall total symptom scores 
(MPN TSS) were higher for females than males (22.8 [SD=17.0] vs. 20.3 
[SD=16.3], p<0.001; Figure 2).  Females also had higher individual symptoms 
scores for all individual MPN symptoms that met statistical significance (Figure 
3). This included fatigue (4.5 vs. 4.0, p<0.001), early satiety (2.6 vs. 2.3, p=0.02), 
abdominal pain (1.6 vs. 1.2, p=0.001), abdominal discomfort (2.1 vs. 1.6, 
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p<0.001), headache (2.2 vs. 1.6, p<0.001), concentration difficulties (2.7 vs. 2.3, 
p=0.01), dizziness (2.5 vs. 2.0, p<0.001), numbness (2.6 vs. 2.2, p=0.001), 
insomnia (3.4 vs. 2.4, p<0.001), sad mood (2.6 vs. 2.3, p=0.01), night sweats 
(2.4 vs. 2.0, p=0.002) and bone pain (2.3 vs. 1.6, p<0.001).  Items that did not 
differ between gender included inactivity, sexuality concerns, cough, pruritus, 
fevers, weight loss and overall quality of life.  Fatigue was the most severe 
symptom for both genders.  Symptom prevalence differed for many of the MPN 
individual questions (Figure 4). With the exception of weight loss (males 37.4% 
vs. females 31.7%, p=0.008), women demonstrated higher prevalence of all 
symptoms for all items demonstrating statistical differences from males.  These 
symptoms included abdominal pain (46.0% vs. 40.8%, p=0.02), abdominal 
discomfort (55.2% vs. 50.7%, p=0.046), headache (58.1% vs. 49.1%, p<0.001), 
dizziness (61.0% vs. 56.6%, p=0.046), numbness (64.1% vs. 58.1%, p=0.007), 
insomnia (70.5% vs. 59.9%, p<0.001), night sweats (55.6% vs. 49.8%, p=0.01) 
and bone pain (53.2% vs. 43.4%, p<0.001).   
 
MPN Symptoms by Region/Culture 
 The influence of region/culture was also explored amongst male and 
female patients by comparing the Chinese cohort (n=544) with the remaining 
Western cohort (European and United States of America; n=1462).  Overall, 
female Chinese patients expressed more severe symptoms related to headaches 
(2.5 vs. 2.0, p=0.01), dizziness (3.1 vs. 2.2, p<0.0001), sexuality difficulties (4.6 
vs. 2.9, p<0.0001), fevers (0.6 vs. 0.4, p=0.005) and weight loss (1.6 s. 1.1, 
 12
p=0.001) with higher Total Symptom Scores (22.2 vs. 19.5, p=0.023) and worse 
overall QOL (3.1 vs. 2.8, p=0.048; Figure 5). Highest scores for Chinese females 
were noted for sexuality related complaints (4.6/10) and insomnia (3.3/10). In 
contrast, Western females described worse fatigue (4.7 vs. 4.0, p=0.0003) and 
abdominal pain (1.7 vs. 1.1, p=0.0004). Highest scores for Western females were 
noted for fatigue (4.7/10) and insomnia (3.4/10).  
 
 Similar to Chinese females, Chinese males also expressed more severe 
symptoms related to headaches (1.9 vs. 1.4, p=0.001), dizziness (2.6 vs. 1.8, 
p<0.0001), sexuality problems (4.5 vs. 3.4, p=0.0001), fevers (0.7 vs. 0.4, 
p=0.0002) and weight loss (2.2 vs. 1.1, p<0.0001; Figure 6) than Western 
counterparts. Highest scores for Chinese males were noted for sexuality 
concerns (4.5/10) and fatigue (3.9/10). Similarly, highest scores for Western 
males were noted for fatigue (4.1/10) and sexuality concerns (3.4/10). 
 
Discussion 
 The diversity of myeloproliferative neoplasms has made full 
characterization of their symptom profiles challenging.  Polycythemia vera, 
essential thrombocythemia and myelofibrosis may concurrently impair length of 
survival, quality of life, and invariably efforts to manage both. For decades, MPN 
gender differences have been observationally documented but remained of low 
investigational priority given the paucity of exploratory tools. Objective 
examination of symptom heterogeneity has emerged an option via the 
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development of MPN-specific PRO tools (MF-SAF, MPN-SAF and MPN-10), 
enhanced precision of risk scoring algorithms and advancements in genomic 
sequencing.5,11,12 Applying many of these novel instruments, this study 
represents the first large-scale investigation into the correlates between gender, 
clinical features and patient symptomatology. 
 
 This investigation yielded number of important findings.  The first is the 
observance that female patients were more likely to have ET (48.6%) and male 
patients were more likely to have PV (30.3%).  Consistent with previous findings, 
literature has historically supported a prevalence of females in ET and 
prevalence of males in PV.13-17 Gender discrepancies within the hematological 
malignancies are not unique to MPNs.  Other disorders such as acute 
lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and multiple 
myeloma (MM), have all demonstrated similar discordances in gender 
prevalence.18,19 Though the etiology driving this observation remains unclear, sex 
chromosome complement/aberrations/aneuploidy, sex-steroid influence, 
immune-competence, and gene expression may be potential contributors.20-23 
Evaluation of these prospective sources was beyond the scope of this 
investigation but are worthy of exploring in future studies. 
 
 This study also found males and females to have similar rates of 
thrombosis. Previous investigations have shown that thrombotic risk typically 
differs by sex amongst the MPN subtypes.2,24-26   Within the ECLAP study, 
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female PV patients were more likely to suffer thrombotic complications (11% vs 
8%), particularly within the splanchnic system.27 Similarly, a recent international 
collaborative study of 891 ET patients identified that on multivariable analysis, 
only male gender was predictive of venous thrombosis.28 Gender also appears to 
influence the location of vascular events.  A recent investigation identified that 
women were more likely to experience macrothrombosis within the abdominal 
venous system (hepatic, portal, mesenteric or splenic veins) whereas males were 
more likely to experience deep venous system events including extremity 
thrombosis and pulmonary emboli.16   
 
 Though gender influence on thrombosis pathogenesis remains unclear, 
mounting evidence suggests that both the type and ratio of circulating sex-
steroids plays an important role in the thrombotic cascade. In an investigation 
involving exogenous sex-steroid administration, ET patients exposed to hormone 
replacement therapy (HRT; estrogen only) had similar rates of arterial and 
venous thrombosis when compared to ET patients not on therapy.29 Importantly, 
this finding conflicts with studies of healthy populations where females using HRT 
have been observed to be at greater thrombotic risk. However, ET patients 
utilizing oral contraceptive therapy (OCP, estrogen and progesterone combined) 
had increased rates of venous thrombosis, and specifically, a 5-fold increased 
risk of splanchnic venous thrombosis (15% vs. 3%). From a hormonal standpoint, 
it remains unclear why male ET patients face higher thrombotic risk than females 
and serves to show that pathogenesis is likely multifactorial.  In our population 
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specifically, it remains unclear why males and females demonstrated similar 
rates of thrombosis, independent of subtype. It should be noted that this 
investigation also did not specify the location or type of thrombosis (arterial vs. 
venous) which may have further shed light into this discrepancy. 
 
 We find it interesting that despite not differing by total number of 
thrombotic events, our female population still described more abdominal pain.  
Given that this study utilized reported events only (and did not prospectively 
investigate for thrombosis), it is possible that unrecognized macrothrombosis was 
present in the abdominal cavity of female patients, accounting for 
symptomatology. Alternatively, the source may relate to discrepancies in splenic 
size which were not investigated in this study or symptom expression differences 
which are discussed below.  
 
 The observation that males and females reported different symptom 
burdens remains a major finding. Overwhelmingly, females described symptoms 
with greater frequency and severity than males. In particular, abdominal 
complaints (abdominal pain, discomfort) and microvascular symptoms 
(headache, fatigue, insomnia, concentration difficulties, dizziness) dominated the 
female symptom burden.  Factors that might have accounted for higher symptom 
scores (such as anemia, high-risk disease status or increased counts of 
hemorrhagic/thrombotic complications) were not observed at higher rates in 
females. In fact, males were more likely to have increased transfusion 
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requirements (despite describing less fatigue) and thrombocytopenia. The source 
of these observations is uncertain.  It is well recognized that the prevalence of 
abdominal pain is higher among females.30 Irritable bowel syndrome (IBS), a 
chronic syndrome of abdominal symptoms characterized by pain, discomfort and 
alterations in bowel habits, has been reported to exist in a female-to-male ratio of 
3:1 and remains a common source of abdominal complaints in younger 
populations 31 However, the prevalence of IBS declines in individuals over 60 and 
given the average age of MPN females, IBS is unlikely to serve as a primary 
symptom driver. As we consider patient symptomatology, it is plausible that in 
addition to facing higher macrovascular risks, females also incur more 
microvascular events. Microthrombosis contributes to microvascular symptoms 
(lightheadedness, dizziness, vertigo, concentration problems, numbness/tingling 
and sexual dysfunction) by compromising endothelial function and inducing local 
hypoxia.32 In this study, females clearly described microvascular symptoms more 
frequently and with more severity than males.  Mechanisms that may account for 
discrepant risks of microvascular dysfunction are worthy of further exploration 
and may parallel those driving macrothrombosis. Underreporting of 
microvascular symptoms by males is also a potential source and discussed 
further below. Congruent with previous investigations, males and females 
described similar degrees of sexual dysfunction and fatigue remained the most 
symptomatic facet of the disease burden. 
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 Patient ethnicity and culture also appear to contribute to symptom burden.  
Variations in symptom expression were noted when Western and Eastern 
patients were compared. Independent of gender, Chinese patients described 
more microvascular symptoms (headaches, dizziness) and more concerns 
related to sexuality.  In contrast, fatigue was the most prominent symptom for 
Western male and female patients.  Eastern and Western MPN variations 
underscored by the presence of fundamental biological and clinical differences 
have been increasingly discussed within the literature.33,34 For example, Eastern 
myelofibrosis patients are more likely to be younger and less likely to struggle 
with constitutional symptoms or splenomegaly.  Survival differences between the 
two cohorts has also been observed, with median survival slightly improved in 
those of Chinese ethnicity.  Given the subjectivity inherent to symptom reporting, 
it remains unclear whether the differences in MPN-SAF scoring between races 
were related to norms of cultural expression (exp. willingness to verbalize 
sexuality complaints) or the natural outworkings of true genotypic and phenotypic 
variances between races. 
 
 The potential that our observations relate to reporting discrepancies is 
also an important discussion.  Within the literature, females tend to describe 
more numerous and more intense symptoms than males, independent of location 
or organ system. In a study of 13,538 non-patient community residents, 
participants evaluated the lifetime prevalence of non-menstrual complaints and 
20 of the 22 most common symptoms were vocalized more frequently by 
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females.35 Similarly, experimental studies involving induction of pain have shown 
females to have a lower threshold of pain tolerance and report more symptoms 
than males.36 Driving these findings may be biological differences in somatic and 
visceral sensation, sex-influenced descriptiveness in symptom labeling and 
reporting, social acceptance of symptom revelation, sex-variances in the 
prevalence of depression and anxiety and gender biases inherent to the research 
process. Some studies have suggested that females engender greater bodily 
vigilance, potentially as an innate contrivance to optimize fertility.37,38 Other 
studies advocate that social cues have impressed upon males the importance of 
limiting expression of discomfort/illness, upholding a stoic appearance and 
underemphasizing complaints.39  
 
 Independent of the source, we find it intriguing that MPN females scored 
the same quality of life despite more frequent and severe symptomatology. The 
literature supports health-related quality of life as typically being rated lower 
among females. This has traditionally been attributed to the higher prevalence of 
disability and chronic conditions in this population.40 However, in this study 
comorbidities were similar between the two sexes.  It is plausible that MPN 
females have socially adapted to compensate for their intensified symptomatic 
burdens.  Alternatively, female patients may simply be more disposed to vocalize 
their complaints.  We also note that females described higher symptom burdens 
but maintained similar risk scores to men. This information corroborates previous 
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findings of the MPN Symptom Burden study that identified MPN symptoms are 
not surrogates for disease severity.4 
 
 It is important to recognize that there are a number of limitations to this 
exploratory investigation.  The first is that the term ‘gender’ is being used 
synonymously with genotypically-defined ‘sex’.  As stated, the surveys allowed 
patients to self-report their sex as either ‘male’ or ‘female’. Though it may be 
assumed that the recorded value referred to genotypic makeup, it is possible that 
some patients recorded their ‘gender identity’ instead, which may not be 
synonymous with chromosomal makeup. Should this have occurred, we believe 
number of cases small and likely consistent with the prevalence of discordant 
associations in the community. We furthermore lack information on the exact 
location of these events (peripheral vs. central). We also note that males also 
had increased transfusion requirements despite similar rates of anemia.  We 
suspect that this likely related to the averaging of pre- and post-transfusion 
hemoglobin checks within males, resulting in a falsely high hemoglobin level.  It 
is worthy to note that the majority of patients within this MPN population were of 
low to intermediate risk which potentially skews symptom burden towards lower 
values.  Though evaluation of symptom burden between genders by risk 
category was beyond the scope of this study, future investigations could further 
explore this to see if symptom progression differs between the sexes.  It is 
important to note that the imposed ‘self-reporting’ format also has inherent flaws. 
However, we believe the use of validated MPN-specific PRO tools greatly 
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improves the cogency of the results.  In addition, medical team members were 
primarily responsible for all data collection not related to symptom expression, 
conceivably limiting errors in the recording process.  It is regrettable that driver 
mutations was not available for analysis as this may have offered insightful 
information. 
 
 The convergence of technological innovations with novel symptom 
assessment tools has revolutionized the treatment landscape for MPNs.  As 
evidenced, few fields of study can boast of the rapidity and cooperative manner 
via which pioneering research has translated into improved patient outcomes.   In 
this study, we’ve determined that gender integrally relates to disease features 
and symptom burden.   Results further underscore the importance of considering 
each sex individually as treatment regimens are built.  Understanding that males 
may be less likely to vocalize their MPN symptoms should influence clinicians to 
explore potentially under-expressed complaints.  Similarly, acknowledging that 
females may face greater symptom burdens should motivate providers to 
consider novel therapies and explore trial options. This exploratory study affirms 
the importance including gender as a contributor to heterogeneity and point of 
investigation in future studies. 
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Table 1.  MPN Patient Demographics by Gender  
 
 
Females 
(N=1089) 
Males 
(N=917) 
Total 
(N=2006) P Value 
     
Mean Age 59.3 (14.36) 60.7 (12.64) 59.9 (13.61)   0.02 
Age <60 532 (48.9%) 397 (43.4%) 929 (46.4%)   0.01 
MPN Subtype (n, %) 
      <0.001 
    ET 528 (48.6%) 302 (33.0%) 830 (41.5%)   
    PV 329 (30.3%) 382 (41.8%) 711 (35.5%)   
    MF 230 (21.2%) 230 (25.2%) 460 (23.0%)   
MF (n, %) 
        0.01 
    PMF 142 (61.7%) 172 (74.8%) 314 (68.3%)   
    ET-MF 50 (21.7%) 33 (14.3%) 83 (18%)   
    PV-MF 38 (16.5%) 25 (10.9%) 63 (13.7%)   
Mean MPN Duration (years, SD) 7.2 (7.0) 6.4 (6.5) 6.8 (6.9) 0.03  
Language (n, %) 
        0.19 
    Chinese 292 (26.8%) 252 (27.5%) 544 (27.1%)   
    Dutch 118 (10.8%) 118 (12.9%) 236 (11.8%)   
    English 75 (6.9%) 82 (8.9%) 157 (7.8%)   
    French 257 (23.6%) 205 (22.4%) 462 (23%)   
    German 72 (6.6%) 41 (4.5%) 113 (5.6%)   
    Italian 103 (9.5%) 83 (9.1%) 186 (9.3%)   
    Spanish 112 (10.3%) 82 (8.9%) 194 (9.7%)   
    Swedish 60 (5.5%) 54 (5.9%) 114 (5.7%)   
MF DIPSS Risk (n, %) 
        0.55 
    Low 24 (20.7%) 19 (16.0%) 43 (18.3%)   
    Int-1 64 (55.2%) 64 (53.8%) 128 (54.5%)   
    Int-2 24 (20.7%) 33 (27.7%) 57 (24.3%)   
    High 4 (3.4%) 3 (2.5%) 7 (3%)   
ET IPSET Risk (n, %) 
        0.11 
    Low 176 (37.8%) 86 (32.7%) 262 (36%)   
    Int 218 (46.9%) 122 (46.4%) 340 (46.7%)   
    High 71 (15.3%) 55 (20.9%) 126 (17.3%)   
PV Risk (n, %) 
        0.30 
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    Low 49 (19.1%) 66 (22.1%) 115 (20.7%)   
    Int 71 (27.7%) 94 (31.4%) 165 (29.7%)   
    High 136 (53.1%) 139 (46.5%) 275 (49.5%)   
Anemia (<10 g/dL; n, %) 78 (8.4%) 66 (8.7%) 144 (8.5%)   0.84 
Leukopenia (<4.0 x 10(9)/L) 91 (9.9%) 77 (8.7%) 168 (10.0%)   0.83 
Thrombocytopenia (<150 x 10(9)/L; n, 
%) 76 (8.2%) 105 (13.9%) 181 (10.7%) <0.001 
Mean hemoglobin (SD) 13.0 (3.36) 13.8 (2.86) 13.4 (3.17) <0.001 
Mean WBC (SD) 8.5 (6.09) 9.5 (8.24) 8.9 (7.15)  0.004 
Mean Platelet Count (SD) 454.1 (269.42) 399.5 (267.21) 429.5 (269.72) <0.001 
Lab Abnormality (n, %) 206 (22.2%) 200 (26.3%) 406 (24%)  0.049 
Prior Thrombosis (n, %) 217 (20.4%) 200 (22.2%) 417 (21.2%)   0.34 
Prior Hemorrhage 55 (5.1%) 52 (5.7%) 107 (5.4%)   0.53 
RBC Transfusion Requirements 53 (4.9%) 67 (7.3%) 120 (6.0%)   0.02 
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Legend 
Figure 1.  Percentage of MPN patients who have received prior therapies (x axis) compared by gender. 
 
Figure 2.   Evaluation of total number of patients in each gender (y axis) when compared by total MPN-SAF TSS value (x 
axis). 
 
Figure 3.  Comparison of Total MPN SAF (y axis) for individual items (x axis) between male and female genders. 
 
Figure 4.  Comparison of MPN SAF symptom prevalence (y axis) for individual items (x axis) by gender. 
 
Figure 5.  Comparison Chinese and Western female patient scores for individual MPN-SAF items. 
 
Figure 6.  Comparison Chinese and Western male patient scores for individual MPN-SAF items
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Appendix 1:  MPN-SAF PRO Development and Validation 
 
 The MPN-SAF included existing questions from the Myelofibrosis 
Symptom Assessment Form (MF-SAF; fatigue, early satiety, abdominal 
pain, abdominal discomfort, inactivity, cough, night sweats, pruritus, bone 
pain, fever, weight loss and quality of life) and was expanded to include 
‘problems with concentration’, ‘difficulty sleeping’, ‘numbness/tingling’, 
‘depression or sad mood’ and ‘problems with sexual desire or function’.  All 
questions were scored on a scale from 0 (as good as it can be/absent) to 
10 (as bad as it can be/worst-imaginable).  The survey was drafted in 
English format and translated into other languages via an established 
Patient Reported Outcome translation method. Translation for each 
language involved three independent survey translations created by 
translators fluid in both English and the respective language requiring 
translation.  A fourth translator then compares the three translator 
manuscripts to develop a consensus translation.    
 
 Upon completion of the survey, patients were recruited from 
academic, government-funded and private practice international medical 
centers. Patients were requested to self-complete the MPN-SAF  during an 
office visit.  Patients were also provided the opportunities to include 
additional symptoms omitted from the survey via open-ended questions.  
Physicians who were blinded to patient responses were required to rank 
patient symptoms on the same 0-10 scale as well as document patient 
disease status including laboratory data, treatment history and prognostic 
scores.  Anova F tests or 2-sample t tests were used to assess continuous 
variables whereas x2 tests were used to compare categorical variables.  
The relationships between variables was assessed using Pearson 
correlations.  Patient scores between language groups were adjusted by 
disease type using general linear models and intraclass correlation 
coefficient (ICC) was analyzed on the basis of a 2-way ANOVA model. 
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